Browsing Tag
CNS therapeutics
8 posts
Can AI-guided delivery platforms reshape CNS drug development? Inside the Mercury Bio and Meta-Flux alliance
Mercury Bio and Meta-Flux are teaming up to tackle Parkinson's and Alzheimer's with AI-powered simulation and next-gen delivery. Can this reshape CNS drug development?
Vistagen shares topline PALISADE-3 Phase 3 data for fasedienol in acute social anxiety treatment
Find out how Vistagen’s PALISADE-3 Phase 3 results for fasedienol reshape its social anxiety strategy and investor expectations.
What Vanda’s December FDA deadlines could mean for motion sickness drug market leadership
Vanda Pharmaceuticals confirms FDA extension of tradipitant clinical hold review to December 5, while motion sickness NDA remains on track for December 30 decision.
Vyepti and Rexulti power Lundbeck (CPH: LUN) to raise 2025 guidance after 22% adjusted EBITDA surge
Lundbeck lifts 2025 guidance as Vyepti and Rexulti drive 22% EBITDA growth. Explore the neuroscience-focused strategy powering its latest earnings surge.
UZEDY wins FDA nod for Bipolar I maintenance therapy, boosting Teva and Medincell’s psychiatric drug portfolio
FDA expands UZEDY approval to Bipolar I maintenance therapy — explore how Teva and Medincell’s long-acting risperidone strategy is reshaping psychiatric care.
Argent Biopharma (ASX: RGT) shares rise 7.69% as U.S. in vivo study validates ArtemiC efficacy in Alzheimer’s model
Argent Biopharma gains 7.69% after U.S. in vivo Alzheimer’s study validates ArtemiC’s plaque-reducing effects. Read more on RGT’s strategy and market outlook.
Klotho Neurosciences begins manufacturing KLTO-202 gene therapy to advance clinical trials in ALS
Klotho Neurosciences begins KLTO-202 manufacturing to prepare for ALS clinical trials, with a gene therapy targeting neuroprotection in spinal neurons.
Marksans Pharma secures US FDA approval for multiple strengths of Pregabalin capsules in key neuropathic pain segment
Marksans Pharma wins US FDA approval for multi-strength Pregabalin capsules, targeting a USD 263M neuropathic pain market in the United States.